Ultragenyx Pharmaceutical | RARE - Ordinary Share Capital


Ultragenyx Pharmaceutical reported $96.35M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.31B
Cash and Equivalent USD 166.11M
Cost of Sales USD 23M
Current Assets USD 719.79M
Current Liabilities USD 293.24M
Debt USD 36.3M
EBIT USD -193.57M
EBITDA USD -91.34M
Employees 1.29K
EPS Earnings Per Share USD -1.17
Equity Capital and Reserves USD 151.29M
Gross Profit on Sales USD 143.49M
Interest Expense on Debt USD 14.04M
Interest Income USD 5.79M
Loan Capital USD 782.75M
Market Capitalization USD 2.61B
Net Income USD -114.95M
Operating Expenses USD 274.38M
Operating Profit USD -193.57M
Ordinary Share Capital USD 96.35M
Pre-Tax Profit USD -114M
Sales Revenues USD 166.5M
Selling and Administration Expenses USD 86.65M
Stock USD 46.5M
Trade Creditors USD 34.24M
Trade Debtors USD 124.46M

Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 167.36M 167.35M Jun/2025
Agios Pharmaceuticals USD 58.04M 57.96M Jun/2025
Alnylam Pharmaceuticals USD 130.98M 129.67M Jun/2025
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
Insmed USD 211.11M 209.29M Jun/2025
Ionis Pharmaceuticals USD 159.2M 159.04M Jun/2025
Kyowa Hakko Kirin JPY 523.49M 26.22B Jun/2025
MacroGenics USD 63.21M 62.58M Jun/2025
Moderna USD 389M 388.96M Jun/2025
Neurocrine Biosciences USD 99M 0 Jun/2025
PTC Therapeutics USD 79.38M 79.3M Jun/2025
Regeneron Pharmaceuticals USD 106.4M 106.4M Jun/2025
Sarepta Therapeutics USD 97.71M 97.7M Jun/2025
Ultragenyx Pharmaceutical USD 96.35M 2.45M Jun/2025
Vertex Pharmaceuticals USD 256.3M 253.7M Jun/2025